Different oncologic outcomes in early-onset and late-onset sporadic colorectal cancer: A regression analysis on 2073 patients

C Foppa, A Maroli, S Lauricella, A Luberto, C La Raja… - Cancers, 2022 - mdpi.com
C Foppa, A Maroli, S Lauricella, A Luberto, C La Raja, F Bunino, M Carvello, M Sacchi
Cancers, 2022mdpi.com
Simple Summary Early-onset colorectal cancer (EOCRC) is on the rise. Reasons are
unknown and comparative results about long-term survival are still widely debated. This
study aimed to explore the effect of early age of onset in a surgical population of sporadic
colorectal cancer patients. Early age of onset resulted independently and is associated with
worse oncologic outcomes also in stage I patients. This study suggested that EOCRC may
have a more aggressive tumoral phenotype compared with late-onset CRC. A better …
Simple Summary
Early-onset colorectal cancer (EOCRC) is on the rise. Reasons are unknown and comparative results about long-term survival are still widely debated. This study aimed to explore the effect of early age of onset in a surgical population of sporadic colorectal cancer patients. Early age of onset resulted independently and is associated with worse oncologic outcomes also in stage I patients. This study suggested that EOCRC may have a more aggressive tumoral phenotype compared with late-onset CRC. A better understanding of the biology of EOCRC is needed to revise —and eventually modify—current strategies of treatment and surveillance.
Abstract
The incidence of colorectal cancer (CRC) is increasing in the population aged ≤ 49 (early-onset CRC-EOCRC). Recent studies highlighted the biological and clinical differences between EOCRC and late-onset CRC (LOCRC-age ≥ 50), while comparative results about long-term survival are still debated. This study aimed to investigate whether age of onset may impact on oncologic outcomes in a surgical population of sporadic CRC patients. Patients operated on for sporadic CRC from January 2010 to January 2022 were allocated to the EOCRC and LOCRC groups. The primary endpoint was the recurrence/progression-free survival (R/PFS). A total of 423 EOCRC and 1650 LOCRC was included. EOCRC had a worse R/PFS (p < 0.0001) and cancer specific survival (p < 0.0001) compared with LOCRC. At Cox regression analysis, age of onset, tumoral stage, signet ring cells, extramural/lymphovascular/perineural veins invasion, and neoadjuvant therapy were independent risk factors for R/P. The analysis by tumoral stage showed an increased incidence of recurrence in stage I EOCRC (p = 0.014), and early age of onset was an independent predictor for recurrence (p = 0.035). Early age of onset was an independent predictor for worse prognosis, this effect was stronger in stage I patients suggesting a potentially—and still unknown—more aggressive tumoral phenotype in EOCRC.
MDPI
以上显示的是最相近的搜索结果。 查看全部搜索结果